Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $2 Price Target (Firm Name Change From RBC To HC Wainwright & Co.)

Author: Benzinga Newsdesk | February 12, 2025 11:58am

CORRECTION:HC Wainwright & Co. analyst Joseph Pantginis reiterates Aptose Biosciences (NASDAQ:APTO) with a Buy and maintains $2 price target.(Firm Name Change From RBC To HC Wainwright & Co.)

Posted In: APTO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist